Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline

Introduction The prognostic utility of cerebrospinal fluid (CSF) phosphorylated tau 217 (p-tau217) and p-tau181 is not understood. Methods Analyses included 753 Mayo Clinic Study on Aging participants (median age = 71.6; 57% male). CSF amyloid beta (A beta)42 and p-tau181 were measured with Elecsys immunoassays. CSF p-tau181 and p-tau217 were also measured with Meso Scale Discovery (MSD). We used Cox proportional hazards models for risk of mild cognitive impairment (MCI) and linear mixed models for risk of global and domain-specific cognitive decline and cortical thickness. Analyses were stratified by elevated brain amyloid based on CSF A beta 42 or amyloid positron emission tomography for those with imaging. Results CSF p-tau217 was superior to p-tau181 for the diagnosis of Alzheimer's disease (AD) pathology. CSF MSD p-tau181 and p-tau217 were associated with risk of MCI among amyloid-positive individuals. Differences between CSF p-tau measures predicting cortical thickness were subtle. Discussion There are subtle differences for CSF p-tau217 and p-tau181 as prognostic AD markers.

Automated summary

CSF phosphorylated tau 217 and p-tau181 have subtle differences in predicting Alzheimer's disease, CSF MSD p-tau181 and p-tau217 are associated with MCI risk among amyloid-positive individuals, and there are subtle differences in predicting cortical thickness.